Improving HIV prevention and care for adolescents and young adults in Uganda
Official title: Implementation Science to Understand and Design Stakeholder Informed Innovative Interventions to Improve Adolescent and Youth HIV Prevention and Care Continuums in Rural and Urban Uganda
Funded at Mu-Jhu Care · NIH-11395131 · Data updated 2026-11-12
The team will try youth-friendly ways to deliver long-acting HIV prevention and better care for 15–24 year-olds in rural and urban Uganda.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mu-Jhu Care NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project start | September 8, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $172,619 |
| NIH project number | 3UG1HD113241-03S2 |
| Project ID | NIH-11395131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are adolescents and young adults aged about 15–24 in Uganda who are either at high risk for HIV and could benefit from long-acting PrEP or are living with HIV and need support to reach viral suppression.
✕Less likely to help
People older than the study age range, those living outside the participating Ugandan communities, or individuals ineligible for cabotegravir or the care models used may not receive direct benefit from this project.
What this research studies
If you join, the project will offer new, community-focused ways to get long-acting HIV prevention shots (cabotegravir) and more supportive care for young people. The study uses simple risk screening to find higher-risk adolescents and combines clinic and community services approved by Uganda's health ministry. It will also deliver a package of youth-tailored supports called SEARCH-Youth to help young people with HIV reach and stay suppressed. The researchers will follow participants in both rural and urban areas to see how these approaches work in everyday settings.
Why it matters
Potential benefit: Could make HIV prevention easier to use and help more young people achieve lasting viral suppression by offering long-acting medication and youth-focused care closer to where they live.
How similar studies have gone: Long-acting cabotegravir has shown strong protection in prior clinical trials, but combining it with youth-focused delivery models and the SEARCH-Youth package in routine Ugandan settings is relatively new.
Where this research is happening
-
Mu-Jhu Care
Kampala, Uganda Active
Researchers
- Principal investigator: Musoke, Philippa — Mu-Jhu Care
- Study coordinator: Musoke, Philippa
Related research
Other NIH-funded projects on the same topics.
-
Making HIV prevention and care easier for Ugandan youth
A Ugandan study is testing ways to help adolescents and young adults (15–24) prevent HIV and stay healthy, using long-acting PrEP and youth-friendly services.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan research team is testing practical, youth-focused strategies to help 15-24 year-olds using HIV prevention or treatment services stay healthy and engaged in care.
-
Improving HIV Prevention and Care for Ugandan Adolescents and Young Adults
A Uganda-based research effort aims to boost HIV prevention and care outcomes for 15-24 year-olds by testing practical, community-based strategies to increase PrEP use and viral suppression.
-
Adolescent and Youth HIV Prevention and Care Improvements in Uganda
A UG1 grant is testing ways to help Ugandan teens and young adults (ages 15-24) prevent HIV and stay healthy if they have HIV, using new long-acting PrEP and community care approaches.
-
Malkia Klabu: safer, youth-friendly pharmacies to boost HIV prevention for AGYW in Tanzania
A Tanzania-based project tests a youth-friendly pharmacy model to improve access to HIV prevention and sexual health services for adolescent girls and young women.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan study tests new ways to help teens and young adults (ages 15–24) prevent HIV and stay healthy if they are living with HIV, using community-based options and long-acting PrEP.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.